LOS ANGELES, Feb. 01, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Akorn, Inc. (“Akorn” or “the Company”) (NASDAQ: AKRX ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Akorn disclosed that it received an FDA warning letter on January 9, 2019, based on an inspection of the Company’s manufacturing facility located in Decatur, Illinois. The inspection and subsequent warning letter revealed that Akorn had failed to follow federal regulations on drug manufacturing, despite having communicated the opposite to shareholders. Based on this news, shares of Akorn fell more than 11.6% the same day.
If you are a shareholder who suffered a loss, click here to participate .
We also encourage you to contact Brian Schall, or Sherin Mahdavian, of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com , or by email at brian@schallfirm.com .
The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm Brian Schall, Esq. Sherin Mahdavian, Esq. 310-301-3335 Cell: 424-303-1964 info@schallfirm.com
SOURCE:
The Schall Law Firm
